EVO101
Phase 2Small molecule
EVO101 is one of 78 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Rezzayo
RochePhase 3
Daliresp
AstraZenecaPhase 3
Skyrizi
AbbViePhase 3
Fludara
SanofiPhase 3
Cytosar
TevaPhase 3
Celestone
SSchering-Plough
Phase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
EBGLYSS
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EVO101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVirginia Clinical Research, Inc.